Emory University's Winship Cancer Institute: Study Shows Targeted Therapy For Pediatric High-Risk Hodgkin Lymphoma Reduces Relapse
November 03, 2022
November 03, 2022
ATLANTA, Georgia, Nov. 3 (TNSjou) -- Emory University's Winship Cancer Institute issued the following news release:
A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Winship Cancer Institute of Emory University, Children's Healthcare of Atlanta and Roswell Park Comprehe . . .
A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Winship Cancer Institute of Emory University, Children's Healthcare of Atlanta and Roswell Park Comprehe . . .